Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.  The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections.  Speroâ€™s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens.  The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.